Calliditas jumps after $1.1 bln buyout by Japan's Asahi

Calliditas Therapeutics AB

28/05/2024 13:25

** U.S.-listed shares of Calliditas Therapeutics  CALT.O 
gain 71% at $38.31 in premarket trading after Japan's Asahi
Kasei  3407.T  offered to buy co for around $1.1 bln 
    ** Stockholm-listed shares  CALTX.ST  also up 78.2% 
    ** Asahi's offer of 208 crowns per share for CALT represents
an 83% premium on its closing price of 113.6 crowns on Monday 
    ** With the deal, Asahi gets access to CALT's kidney disease
drug Tarpeyo as well as a mid-stage development candidate which
is being developed for treating a liver disease 
    ** As of last close, U.S.-listed shares are down ~13% YTD

 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))